Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Population PK/PD study of voriconazole in HIV-associated talaromycosis
ChiCTR2400079398Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of voriconazole in talaromycosis and human immunodeficiency virus infection (HIV), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Plasma concentration, Talaromyces marneffei colony forming units count and 3 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
voriconazole
03
Conditions
talaromycosishuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2400079398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079398.